Side-by-side · Research reference

KPVvsRetatrutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongDraft13/39 cited

BPhase 2Reviewed10/41 cited

KPV

α-MSH C-terminal · Anti-inflammatory

200–500 mcgDaily doseDalle-Pang 2024

AnimalEvidence levelDalle-Pang 2024

HoursHalf-life (est)

SQ / oral / topical · Local · Daily or 2-3×/week

Retatrutide

Triple-receptor agonist · Phase 3

1–12 mgWeekly doseJastreboff 2023

24.2%Body-weight ↓Jastreboff 2023

~6 daysHalf-life (est)

SQ · Abdomen · Once weekly

01Mechanism of Action

Parameter

KPV

Retatrutide

Primary target

Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024

GLP-1R + GIPR + Glucagon receptor (triple agonism)Jastreboff 2023

Pathway

NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024

Triple-receptor activation → ↑insulin (GLP-1+GIP), ↓gastric emptying, ↑lipid handling, ↑energy expenditure (glucagon component)Jastreboff 2023

Downstream effect

Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024

Maximal weight loss across class. Glucagon component drives lipolysis and energy expenditure beyond GLP-1+GIP aloneJastreboff 2023

Feedback intact?

No melanocortin receptor binding

—

Origin

Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024

Synthetic peptide engineered for balanced affinity at three incretin / glucagon receptorsJastreboff 2023

Antibody development

—

02Dosage Protocols

Parameter

KPV

Retatrutide

Standard dose

200–500 mcg / day SQ or oralDalle-Pang 2024

12 mg / week (max efficacy)Jastreboff 2023

Phase 2 trial dose. Phase 3 dosing TBD.

Frequency

Daily or 2–3× per week

Once weekly

Lower / starter dose

100 mcg / day

—

Evidence basis

Animal-strong + emerging clinical data in IBDDalle-Pang 2024

Phase 2 trial; Phase 3 ongoingJastreboff 2023

Duration

4–8 weeks per cycle

Indefinite for chronic indication (presumed)

Reconstitution

Bacteriostatic water (SQ form)

Investigational; not commercially available

Timing

No specific time; often taken with / before meals (oral)

Any time of day

Half-life

Hours (estimated; rapid tissue uptake)

~6 days (estimated from class)

Titration schedule

—

2 mg → 4 mg → 8 mg → 12 mg over 16 weeks

04Side Effects & Safety

Parameter

KPV

Retatrutide

Injection site reaction

Mild irritation

—

GI symptoms

Rare nausea (oral form)

Nausea, vomiting, diarrhea (very common, dose-dependent)Jastreboff 2023

Pigmentation

None (unlike full α-MSH)Dalle-Pang 2024

—

Long-term safety

Limited human data

—

Pregnancy / OB

Avoid — insufficient data

Avoid (insufficient data)

Heart rate

—

↑ resting HR (3–7 bpm at 12 mg)Jastreboff 2023

Glucose handling

—

Glycemic improvement; rare hyperglycemia from glucagon component

Pancreatitis risk

—

Class warning

Thyroid C-cell tumours

—

Class warning (presumed)

Absolute Contraindications

KPV

·Pregnancy / breastfeeding

Retatrutide

·MTC personal or family history (presumed class effect)
·Pregnancy / breastfeeding

Relative Contraindications

KPV

·Active autoimmune disease (theoretical)

Retatrutide

·Severe gastroparesis
·History of pancreatitis
·Severe cardiovascular disease (HR signal)

05Administration Protocol

Parameter

KPV

Retatrutide

1. Reconstitution

Add 1 mL bacteriostatic water to vial per labelling.

Investigational peptide. Research vials reconstituted with bacteriostatic water per label.

2. Form

SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.

SQ — abdomen, thigh, or upper arm. Rotate weekly.

3. Timing

Morning preferred; oral form taken with / before meals.

Once weekly, same day.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

Refrigerate 2–8 °C. Light-protected.

5. Needle

29–31G insulin syringe (SQ form).

27–31G, 4–8 mm insulin syringe.

06Stack Synergy

KPV

+ BPC-157

Strong

View BPC-157 →

KPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.

KPV: 200–500 mcg oral · daily
BPC-157: 250–500 mcg oral or SQ · daily
Primary benefit: Combined anti-inflammation + mucosal repair for gut conditions

Dalle-Pang 2024 Sikiric 2018

Retatrutide

— no documented stacks